Kenai Therapeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $82M
Overview
Engineering stem cell-derived neuronal therapies to repair the brain in neurodegenerative diseases.
NeuroscienceRegenerative Medicine
Technology Platform
A stem cell differentiation platform that produces standardized, clinical-grade dopaminergic neuron precursors for transplantation.
Funding History
1Total raised:$82M
IPO$82M
Opportunities
Potential to deliver a one-time, disease-modifying treatment for millions of patients with Parkinson's disease.
Risk Factors
Immense scientific, clinical, and regulatory hurdles related to cell delivery, long-term safety, and demonstrating durable functional improvement.
Competitive Landscape
Part of a small, pioneering group of companies developing neuronal cell replacement therapies, competing on differentiation technology and clinical strategy.